［1］Solomon EI, Sundaram UM, Machonkin TE. Multicopper oxidases and oxygenases［J］. Chem Rev, 1996, 96(7): 2563-2606.
［2］Que EL, Domaille DW, Chang CJ. Metals in neurobiology: probing their chemistry and biology with molecular imaging［J］. Chem Rev, 2008, 108(5): 1517-1549.
［3］Gunjan D, Shalimar, Nadda N, et al. Hepatocellular carcinoma: an unusual complication of longstanding Wilson disease［J］. J Clin Exp Hepatol, 2017, 7(2): 152-154.
［4］Bock FJ, Tait S. Mitochondria as multifaceted regulators of cell death［J］. Nat Rev Mol Cell Biol, 2020, 21(2): 85-100.
［5］Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins［J］. Science, 2022, 375(6586): 1254-1261.
［6］Tsvetkov P, Detappe A, Cai K, et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress［J］. Nat Chem Biol, 2019, 15(7): 681-689.
［7］Institute of Medicine (US) Panel on Micronutrients. Dietary reference intakes for Vitamin A, Vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc［M］. Washington (DC): National Academies Press (US), 2001.
［8］O′Halloran TV, Culotta VC. Metallochaperones, an intracellular shuttle service for metal ions［J］. J Biol Chem, 2000, 275(33): 25057-25060.
［9］Rosenzweig AC. Copper delivery by metallochaperone proteins［J］. Acc Chem Res, 2001, 34(2): 119-128.
［10］Polishchuk EV, Concilli M, Iacobacci S, et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis［J］. Dev Cell, 2014, 29(6): 686-700.
［11］Roelofsen H, Wolters H, Van Luyn MJ, et al. Copperinduced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion［J］. Gastroenterology, 2000, 119(3): 782-793.
［12］Saroli PC, Schilsky ML. Clinical practice guidelines in Wilson disease［J］. Ann Transl Med, 2019, 7(Suppl 2): S65.
［13］Harvey LJ, Ashton K, Hooper L, et al. Methods of assessment of copper status in humans: a systematic review［J］. Am J Clin Nutr, 2009, 89(6): 2009S-2024S.
［14］Ren F, Logeman BL, Zhang X, et al. Xray structures of the highaffinity copper transporter Ctr1［J］. Nat Commun, 2019, 10(1): 1386.
［15］Lee J, Pena MM, Nose Y, et al. Biochemical characterization of the human copper transporter Ctr1［J］. J Biol Chem, 2002, 277(6): 4380-4387.
［16］Ohgami RS, Campagna DR, McDonald A, et al. The Steap proteins are metalloreductases［J］. Blood, 2006, 108(4): 1388-1394.
［17］Ackerman CM, Lee S, Chang CJ. Analytical methods for imaging metals in biology: From Transition Metal Metabolism to Transition Metal Signaling［J］. Anal Chem, 2017, 89(1): 22-41.
［18］Maybee DV, Ink NL, Ali MAM. Novel roles of MT1MMP and MMP2: Beyond the extracellular milieu［J］. Int J Mol Sci, 2022, 23(17): 9513.
［19］Cobine PA, Moore SA, Leary SC. Getting out what you put in: Copper in mitochondria and its impacts on human disease［J］. Biochim Biophys Acta Mol Cell Res, 2021, 1868(1): 118867.
［20］Kaler SG. ATP7Arelated copper transport diseasesemerging concepts and future trends［J］. Nat Rev Neurol, 2011, 7(1): 15-29.
［21］Ackerman CM, Chang CJ. Copper signaling in the brain and beyond［J］. J Biol Chem, 2018, 293(13): 4628-4635.
［22］Kim BE, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation［J］. Nat Chem Biol, 2008, 4(3): 176-185.
［23］De Feyter S, Beyens A, Callewaert B. ATP7Arelated copper transport disorders: A systematic review and definition of the clinical subtypes［J］. J Inherit Metab Dis, 2023, 46(2): 163-173.
［24］Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease［J］. Nat Rev Dis Primers, 2018, 4(1): 21.
［25］Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia［J］. Nat Rev Cancer, 2022, 22(2): 102-113.
［26］Lopez J, Ramchandani D, Vahdat L. Copper depletion as a therapeutic strategy in cancer［J］. Met Ions Life Sci, 2019, 19(1): 1559-1836.
［27］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.
［28］ElSerag HB. Hepatocellular carcinoma［J］. N Engl J Med, 2011, 365(12): 1118-1127.
［29］RieraRomo M. COMMD1: A multifunctional regulatory protein［J］. J Cell Biochem, 2018, 119(1): 34-51.
［30］Muller P, van Bakel H, van de Sluis B, et al. Gene expression profiling of liver cells after copper overload in vivo and in vitro reveals new copperregulated genes［J］. J Biol Inorg Chem, 2007, 12(4): 495-507.
［31］Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting CuFe balance in hepatocellular carcinoma［J］. J Hepatol, 2022, 76(5): 1138-1150.
［32］Yang M, Wu X, Li L, et al. COMMD10 inhibits tumor progression and induces apoptosis by blocking NFκB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma［J］. Clin Transl Med, 2021, 11(5): e403.
［33］Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used antialcoholism drug and copperbinding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity［J］. Cancer Res, 2006, 66(21): 10425-10433.
［34］Morrison BW, Doudican NA, Patel KR, et al. Disulfiram induces copperdependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma［J］. Melanoma Res, 2010, 20(1): 11-20.
［35］Qiu C, Zhang X, Huang B, et al. Disulfiram, a ferroptosis inducer, triggers lysosomal membrane permeabilization by upregulating ROS in glioblastoma［J］. Onco Targets Ther, 2020, 13(1): 10631-10640.
［36］Lin J, Haffner MC, Zhang Y, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth［J］. Prostate, 2011, 71(4): 333-343.
［37］Zhang H, Chen D, Ringler J, et al. Disulfiram treatment facilitates phosphoinositide 3kinase inhibition in human breast cancer cells in vitro and in vivo［J］. Cancer Res, 2010, 70(10): 3996-4004.
［38］Skrott Z, Mistrik M, Andersen KK, et al. Alcoholabuse drug disulfiram targets cancer via p97 segregase adaptor NPL4［J］. Nature, 2017, 552(7684): 194-199.
［39］Li Y, Wang LH, Zhang HT, et al. Disulfiram combined with copper inhibits metastasis and epithelialmesenchymal transition in hepatocellular carcinoma through the NFκB and TGFβ pathways［J］. J Cell Mol Med, 2018, 22(1): 439-451.
［40］Chiba T, Suzuki E, Yuki K, et al. Disulfiram eradicates tumorinitiating hepatocellular carcinoma cells in ROSp38 MAPK pathwaydependent and independent manners［J］. PLoS One, 2014, 9(1): e84807.
［41］Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copperinduced ferroptosis［J］. Redox Biol, 2021, 46(12): 102122.
［42］Zhang G, Wang Y, Fuchs BC, et al. Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram［J］. Front Oncol, 2022, 12(14): 913736.
［43］Gao X, Huang H, Pan C, et al. Disulfiram/copper induces immunogenic cell death and enhances CD47 blockade in hepatocellular carcinoma［J］. Cancers (Basel), 2022, 14(19): 4715.
［44］Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021［J］. CA Cancer J Clin, 2021, 71(1): 7-33.
［45］BurnettHartman AN, Lee JK, Demb J, et al. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for earlyonset colorectal cancer［J］. Gastroenterology, 2021, 160(4): 1041-1049.
［46］Yelorda KL, Fu SJ, Owens DK. Analysis of survival among adults with earlyonset eolorectal cancer［J］. JAMA Netw Open, 2021, 4(6): e2112878.
［47］GarcíaAlfonso P, Muoz Matín AJ, Morn LO, et al. Oral drugs in the treatment of metastatic colorectal cancer［J］. Ther Adv Med Oncol, 2021, 13: 17588359211009001.
［48］McQuade RM, Stojanovska V, Bornstein JC, et al. Colorectal cancer chemotherapy: The evolution of treatment and new approaches［J］. Curr Med Chem, 2017, 24(15): 1537-1557.
［49］Rad AH, AghebatiMaleki L, Kafil HS, et al. Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment［J］. Crit Rev Food Sci Nutr, 2021, 61(11): 1787-1803.
［50］Rottenberg S, Disler C, Perego P. The rediscovery of platinumbased cancer therapy［J］. Nat Rev Cancer, 2021, 21(1): 37-50.
［51］Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer［J］. Oncogene, 2021, 40(46): 6395-6405.
［52］Zhou J, Kang Y, Chen L, et al. The drugresistance mechanisms of five platinumbased antitumor agents［J］. Front Pharmacol, 2020, 11(20): 343.
［53］Lukanovic D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer［J］. Biomed Pharmacother, 2020, 129(12): 110401.
［54］Li YQ, Yin JY, Liu ZQ, et al. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy［J］. IUBMB Life, 2018, 70(3): 183-191.
［55］Petruzzelli R, Polishchuk RS. Activity and trafficking of coppertransporting ATPases in tumor development and defense against dlatinumbased drugs［J］. Cells, 2019, 8(9): 1080.
［56］Lai YH, Kuo C, Kuo MT, et al. Modulating chemosensitivity of tumors to platinumbased antitumor drugs by transcriptional regulation of copper homeostasis［J］. Int J Mol Sci, 2018, 19(5): 1486.
［57］Shanbhag V, JasmerMcDonald K, Zhu S, et al. ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis［J］. Proc Natl Acad Sci U S A, 2019, 116(14): 6836-6841.
［58］Zhou Y, Zhang Q, Wang M, et al. Effective delivery of siRNAloaded nanoparticles for overcoming oxaliplatin resistance in colorectal cancer［J］. Front Oncol, 2022, 12: 827891.
［59］Nagai M, Vo NH, Shin OL, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells［J］. Free Radic Biol Med, 2012, 52(10): 2142-2150.
［60］Gao W, Huang Z, Duan J, et al. Elesclomol induces copperdependent ferroptosis in colorectal cancer cells via degradation of ATP7A［J］. Mol Oncol, 2021, 15(12): 3527-3544.
［61］Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer［J］. Lancet, 2016, 388(10060): 2654-2664.
［62］Wang L, Chai X, Wan R, et al. Disulfiram chelated with copper inhibits the growth of gastric cancer cells by modulating stress response and Wnt/βcatenin signaling［J］. Front Oncol, 2020, 10: 595718.
［63］Ni M, Solmonson A, Pan C, et al. Functional assessment of lipoyltransferase1 deficiency in cells, mice, and humans［J］. Cell Rep, 2019, 27(5): 1376-1386.
［64］Liu Y, Luo G, Yan Y, et al. A pancancer analysis of copper homeostasisrelated gene lipoyltransferase 1: Its potential biological functions and prognosis values［J］. Front Genet, 2022, 13(18): 1038174.
［65］Abbas G, Krasna M. Overview of esophageal cancer［J］. Ann Cardiothorac Surg, 2017, 6(2): 131-136.
［66］Li ZH, Lu X, Li SW, et al. Expression of ATP7A in esophageal squamous cell carcinoma (ESCC) and its clinical significance［J］. Int J Clin Exp Pathol, 2019, 12(9): 3521-3525.
［67］De Luca A, Barile A, Arciello M, et al. Copper homeostasis as target of both consolidated and innovative strategies of antitumor therapy［J］. J Trace Elem Med Biol, 2019, 24(55): 204-213.